Nautilus Biotechnology Inc Stock Price, News & Analysis

Nautilus Biotechnology (NASDAQ: NAUT) announced that its co-founder and Chief Scientist, Parag Mallick, Ph.D., has been awarded the 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research. The award recognizes Dr. Mallick's significant contributions to imaging research, including his leadership, high-impact publications, and ongoing research and development work. Dr. Mallick will be inducted into the Academy's Council of Distinguished Investigators during the Annual Meeting of the Radiological Society of North America in December 2024.

Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has announced its participation in the Inaugural Guggenheim Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. The presentation will be accessible via live and archived webcast through the 'Investors' section of www.nautilus.bio.

Nautilus Biotechnology (NASDAQ: NAUT) reported its Q3 2024 financial results. The company, which focuses on single-molecule proteome analysis platform development, recorded operating expenses of $19.1 million, unchanged from the previous year. The net loss increased to $16.4 million compared to $15.9 million in Q3 2023. As of September 30, 2024, the company maintained a strong financial position with $221.2 million in cash, cash equivalents, and investments.

Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single molecule protein analysis platforms, has announced it will release its third quarter 2024 financial results on Tuesday, October 29, 2024, before the market opens. The company's management will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss the results, business developments, and future outlook.

Interested parties can access the live audio webcast of the conference call through the 'Investors' section of Nautilus Biotechnology's official website at www.nautilus.bio. This event provides an opportunity for stakeholders and investors to gain insights into the company's financial performance and strategic direction.

Nautilus Biotechnology (NASDAQ: NAUT) has appointed Ken Suzuki as Chief Marketing Officer. Suzuki, a 25-year veteran from Agilent Technologies, brings extensive experience in mass spectrometry and proteomics to Nautilus, a company developing a single-molecule protein analysis platform. This strategic hire comes as Nautilus prepares to launch its Proteome Analysis Platform.

Suzuki's background includes leadership roles in Agilent's Mass Spectrometry division, Strategic Program Office, and Spectroscopy department. His expertise spans marketing, product development, finance, and R&D in the life sciences sector. Nautilus CEO Sujal Patel expressed enthusiasm about Suzuki's potential impact on bringing the company's platform to researchers worldwide.

Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 4, 2024, at 7:00 a.m. Eastern Time.

This event presents an opportunity for investors and interested parties to gain insights into Nautilus's innovative proteomics platform. A live and archived webcast of the presentation will be accessible through the 'Investors' section of the company's website at www.nautilus.bio, allowing for widespread access to the discussion.

Nautilus Biotechnology (NASDAQ: NAUT) reported its Q2 2024 financial results, showcasing progress in its single-molecule proteome analysis platform development. Operating expenses increased 9% to $20.8 million, primarily due to headcount growth. The company reported a net loss of $18.0 million, up from $15.8 million in the same period last year. As of June 30, 2024, Nautilus maintained a strong financial position with $232.9 million in cash, cash equivalents, and investments. CEO Sujal Patel emphasized the company's pioneering approach to overcome limitations in traditional protein analysis methods, focusing on both targeted proteoform analysis and broadscale discovery in proteomics.

Nautilus Biotechnology (NASDAQ: NAUT) has announced it will release its second quarter 2024 financial results on July 30, 2024, before the market opens. The company will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results, recent business developments, and future outlook. Interested parties can access the live audio webcast via the 'Investors' section of Nautilus' website at www.nautilus.bio.

Nautilus Biotechnology, a leader in single-molecule protein analysis, will join the Goldman Sachs 45th Annual Global Healthcare Conference. The event is set for June 10, 2024, at 8:40 a.m. ET. Nautilus' management will participate in a fireside chat, which will be available via live and archived webcast on their investor relations page.